Background: For patients with metastatic upper tract urothelial carcinoma (UTUC), the preferred first-line treatment is platinum-based chemotherapy. Immunotherapy can be considered a subsequent treatment if the chemotherapy is ineffective or the disease progresses. However, how should treatment be administered if immunotherapy is useless and the patient cannot take chemotherapy? Especially in patients who have metastasized after radical nephroureterectomy (RNU).
Case Presentation: A 68-year-old woman was admitted to the hospital due to left flank pain for two weeks and was diagnosed with metastatic UTUC after RNU. The patient underwent systemic chemotherapy with gemcitabine and cisplatin (GC), as well as reduced-dose GC, but developed myelosuppression. Immunotherapy was ineffective, so Disitamab vedotin (RC48) was chosen.
Results: Disitamab vedotin (RC48) monotherapy was administered for 13 cycles, during which thyroid function remained normal, the patient responded well to the treatment, and the disease was controlled well. In the subsequent two years of follow-up, there was no disease recurrence.
Conclusion: The long-term treatment regimen with RC48 is feasible for metastatic UTUC after RNU, and RC48 monotherapy is suitable as first-line therapy for selected patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11427362 | PMC |
| http://dx.doi.org/10.3389/fonc.2024.1419882 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression.
Front Oncol
December 2024
Department of Oncology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Objective: To explore the efficacy of c in the multiline treatment of late-stage lung adenocarcinoma with Her-2 overexpression and epidermal growth factor receptor (EGFR) mutations.
Methods: We summarize the diagnosis and treatment of a female patient with EGFR 21L858R mutation combined with Her-2 overexpression in advanced lung adenocarcinoma, and analyze the effect of c in her treatment process.
Results: The patient was diagnosed with lung adenocarcinoma 8 years ago.
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase 1b/2 dose-escalation and dose-expansion study.
Ann Oncol
December 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital, Beijing, China. Electronic address:
Background: HER2-targeted antibody-drug conjugates (ADCs) such as disitamab vedotin (DV) and trastuzumab deruxtecan (T-Dxd) have emerged as effective treatment options and received regulatory approvals for HER2 expressing locally advanced or metastatic urothelial carcinoma (la/mUC). In addition, ADCs in combination with immunotherapy have demonstrated anti-tumor activity. The current study aimed to evaluate the combination of DV and toripalimab in patients with la/mUC.
View Article and Find Full Text PDFEfficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study.
Front Oncol
November 2024
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Article Synopsis
- A study evaluated the effectiveness and safety of Disitamab Vedotin (RC48) for treating advanced HER2-positive and HER2-low metastatic breast cancer (MBC) among Chinese patients.
- *A total of 154 patients were analyzed, revealing a median progression-free survival of 5.06 months and an objective response rate of 36.36%, with HER2-positive patients faring better than those with low HER2 expression.
- *The results indicate that RC48 is a promising treatment with a good safety profile, and combining it with other therapies could enhance its effectiveness for these patients.
Efficacy of disitamab vedotin in non-small cell lung cancer with alterations: a multicenter, retrospective real-world study.
Front Oncol
November 2024
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Article Synopsis
- This study investigated the effectiveness of a new antibody-drug conjugate, Disitamab vedotin (RC48), in treating advanced non-small cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 alterations, with considerable focus on real-world clinical outcomes.
- The results showed that 95.5% of patients received RC48 in combination therapy, achieving an overall objective response rate (ORR) of 45.5% and a disease control rate (DCR) of 90.9%, with a median progression-free survival (PFS) of 7.5 months.
- Key findings indicated that combination therapies, especially with platinum or TKI, resulted in higher response rates, while most
Real-world application of disitamab vedotin (RC48-ADC) in patients with breast cancer with different HER2 expression levels: efficacy and safety analysis.
Oncologist
November 2024
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210009, People's Republic of China.
Background: Disitamab vedotin (RC48-ADC), an antibody-drug conjugate (ADC), combines specific antibody disitamab with cytotoxicity monomethyl auristatin E to effectively target the human epidermal growth factor receptor 2 (HER2) protein on tumor cells for precise elimination. Recent studies have demonstrated that RC48-ADC offers therapeutic benefits for patients with HER2-positive and HER2-low-expression breast cancer (BC). However, a thorough exploration of its efficacy and safety in real-world settings for patients with metastatic breast cancer (mBC) is currently lacking.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!